2nd Anti-Fibrotic Drug Development Summit (AFDD)

Memo

AFDD (Anti-Fibrotic Drug Development) is the industry definitive fibrosis forum for drug developers focused on organ specific indications to gain cross-disciplinary insights into the next generation of candidates. Join fibrosis leaders as they address challenges in anti-fibrotic drug development through a tighter lens. Critically review demonstrating clinically meaningful anti-fibrotic activity, innovations in preclinical modalities recapitulating fibrosis, and mechanisms of action of emerging candidates. You'll hear from 24 stakeholders including GSK, Janssen and Celgene as this forum equips you with the connections and actionable insights you need to advance your anti fibrotic pipeline. Prices: Conference (Standard): USD 2799.0Conference (Early bird ends Friday August 24, 2018): USD 2499.0Conference (Early bird ends Friday September 21, 2018): USD 2599.0Conference (Early bird ends Friday October 19, 2018): USD 2699.0 URLs: Tickets: https://go.evvnt.com/263771-1?pid=5569 Brochure: https://go.evvnt.com/263771-2?pid=5569 On Tuesday November 27, 2018 at 8:00 am (ends Thursday November 29, 2018 at 5:30 pm) Speakers: Alexey Lugovsky, Chief Development Officer Morphic, Therapeutics, Andy Blanchard, Director External Discovery, GSK, Charles Theuer, Chief Executive Officer, Tracon Pharmaceuticals, David Lagares, Director of the Matrix and Mechanobiology Program, Massachusetts General Hospital, Dennis Andress, Senior Medical Director, Renal Clinical Development, AbbVie, Gerald Horan, Director Translational Science, Celgene, Guillermo Torre-Amione, Chief Medical Officer, Cardiol Therapeutics, Harold Shlevin, Chief Executive Officer, Galectin Therapeutics, Jeffrey Browning, Research Professor, Boston University, Mark Tepper, Chief Executive Officer, Corbus Pharmaceuticals, Martin Phillips, Chief Executive Officer, Opsidio, Masha Poyurovsky, Vice President, Head of Molecular Signalling, Kadmon Pharmaceuticals, Matthew Breyer, Distinguished Scientist, Cardiovascular and Metabolism, Janssen Pharmaceuticals,Peter Blume-Jensen, Chief Executive Officer, Acrivon Therapeutics, Peter Bunyard, Head of Immunology Biology, RedX Pharma, Peter Caravan, Director of the Institute for Innovation in Imaging, Massachusetts General Hospital, Peter Traber, Partner, Alacrita Consulting, Richard Marshall, Vice President, Head of Fibrosis, GSK, Ruogang Zhao, Assistant Professor of Biomedical Engineering, University of Buffalo, Sean Muthian, Executive Director - External Science Innovations, Allergan,Sofia Mayans, Chief Executive Officer, Inficure Bio, Stefan Wawersik, Associate Director, Discovery Biology, Scholar Rock, Viktor Martyanov, Research Scientist, Geisel School of Medicine at Dartmouth Department of Molecular and Systems Biology, Wolfgang Jarolimek, Head of Drug Discovery, Pharmaxis Venue details: Hyatt Regency Cambridge, 575 Memorial Drive, Cambridge, Massachusetts, 02139, United States